Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer
Publication in policy or professional journal


香港中文大学研究人员 ( 现职)

莫树锦教授 (肿瘤学系)

全文

数位物件识别号 (DOI) http://dx.doi.org/10.1016/j.cllc.2012.05.009

引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/47WOS source URL

其它资讯

摘要We present the treatment rationale and study design of the MetLung phase Ill study. This study will investigate onartuzumab (MetMAb) in combination with erlotinib compared with erlotinib alone, as second- or third-line treatment, in patients with advanced non small-cell lung cancer (NSCLC) who are Met-positive by immunohistochemistry. Approximately 490 patients (245 per treatment arm) will receive erlotinib (150 mg oral daily) plus onartuzumab or placebo (15 mg/kg intravenous every 3 weeks) until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death. The efficacy objectives of this study are to compare overall survival (OS) (primary endpoint),

着者Spigel DR, Edelman MJ, Mok T, O'Byrne K, Paz-Ares L, Yu W, Rittweger K, Thurm H
期刊名称Clinical Lung Cancer
出版年份2012
月份11
日期1
卷号13
期次6
出版社CIG MEDIA GROUP, LP
国际标準期刊号1525-7304
电子国际标準期刊号1938-0690
语言英式英语

关键词Biomarkers; Onartuzumab; Second/third-line therapy
Web of Science 学科类别Oncology; ONCOLOGY